TRML: Tourmaline Price to Sales
Unpredictability in clinical trials and regulatory pressure are creating volatility, highlighted by the divergence of the P/S ratio from its historical average for Tourmaline Bio, Inc. (TRML). The current level of captures the real-time valuation of the business relative to its revenue. These risks are mitigated by a lack of direct peers in the orphan disease niche, while a strategic alliance with scientific centers for antibody licensing accelerates the time-to-market for its drug pipeline.
Metric breakdowns and analytics for Tourmaline Corp (TRML)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
- earnings and market ratios statistics:
TRML - Net Profit|Company Profit Forecast Tourmaline Bio, Inc.|TRML - Price to Earnings Ratio|Price to Future Earnings Ratio Tourmaline Bio Inc|TRML - PEG Multiple|Company Value to EBITDA Tourmaline Corp|TRML - Operating profit before deduction of amortization|Earnings per share for the trailing year Tourmaline Bio|TRML - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months tourmalinebio.com|TRML - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Tourmaline Bio, Inc.
- total revenue and sales volume data:
Fundamental company analysis:TRML (tourmalinebio.com)
The P/S multiple reflects the market value of a business relative to its annual sales volume, measuring the premium investors are willing to pay per unit of revenue. An analysis of the revenue valuation ratio for Tourmaline Bio, Inc. (TRML) allows for an assessment of market expectations regarding the capture of the thyroid eye disease treatment niche with the drug tourmaline-001, where the asset's high valuation is justified by the potential for a technological breakthrough in immunology.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA: Market Cap to Revenue|Protagonist Corp - Market Cap to Sales Volume|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Price to Sales kiniksa.com (KNSA)|Market Cap to Revenue GRFS|P/S Multiple Adaptive Biotech|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio BioCryst BCRX|VERA - Market Cap to Revenue|Dianthus Therapeutics, Inc. - P/S Multiple|PHVS - P/S Multiple|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|PGEN (Precigen Corp) - Price-to-Revenue Ratio|PHAR (Pharming Group N.V.) - P/S Multiple|nektar.com (NKTR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Upstream Bio (UPB)|Zenas Bio - Market Cap to Revenue Ratio|P/S Multiple IMNM (Immunome Corp)|Gossamer Bio Corp. (GOSS) - Price to Sales|KALV: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SEPN (septerna.com)|PVLA: P/S Multiple|SVRA (Savara Inc) - Price-to-Revenue Ratio|RIGL (Rigel Pharmaceuticals Inc) - P/S Multiple|AnaptysBio Inc. (ANAB) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|ENGN - Price to Sales|RAPT Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio JBIO|Aclaris - P/S Multiple|Price-to-Revenue Coefficient Kyverna Therapeutics, Inc KYTX|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CABA|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|Market Cap to Revenue Theratechnologies, Inc. (THTX)|Market Cap to Revenue AVTX (Avalo Therapeutics Inc.)|Price-to-Revenue Coefficient Eledon Pharmaceuticals, Inc|Agenus - Market Cap to Revenue|Market Cap to Sales Volume CLYM (climbbio.com)|ZURA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ATYR (aTyr Pharma Inc)|adagene.com (ADAG) - Price-to-Revenue Ratio|Market Cap to Revenue Ikena Oncology|Price-to-Revenue Ratio Shattuck Labs Inc|Price-to-Revenue Ratio EQ|Price-to-Revenue Ratio Connect Biopharma (CNTB)|IMUX: Price-to-Sales Ratio|P/S Multiple ATRA (Atara Bio)|Market Capitalization-to-Revenue Ratio IFRX|X4 Pharmaceuticals - P/S Multiple|ACET - P/S Multiple|celularity.com (CELU) - Price-to-Revenue Ratio|INmune Bio Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|P/S Multiple SABS|P/S Multiple akaritx.com (AKTX)|Enlivex Therapeutics Ltd. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTTB|GeoVax Labs Inc - P/S Multiple|Price-to-Revenue Coefficient Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Bolt Bio (BOLT)|Market Cap to Revenue HCWB (HCW Biologics Inc.)|P/S Multiple aptevotherapeutics.com (APVO)|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX: Market Cap to Revenue Ratio|GRI Bio - P/S Multiple|Price to Sales XORTX Therapeutics Inc|HIND (ReShape Lifesciences) - Market Cap to Revenue|REVB: Market Cap to Sales Volume|Price-to-Revenue Ratio Indaptus Therapeutics|Price to Sales scinai.com SCNI|Market Cap to Revenue CALI (CalciMedica, Inc.)|P/S Multiple affimed.com (AFMD)|Price-to-Revenue Ratio Allakos ALLK|Market Capitalization-to-Revenue Ratio HOOK|IGMS - Price-to-Revenue Ratio|iteostherapeutics.com (ITOS) - Market Cap to Revenue|OCEA: P/S Multiple|TC BioPharm (Holdings) Plc (TCBP) - P/S Multiple|Price-to-Revenue Ratio Third Harmonic Bio, Inc
